1.
Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma. J of Skin. 2018;2:S77. doi:10.25251/skin.2.supp.77